Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow ...
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results